News

The Future of Multiple Sclerosis –⁠ Time for a Change in Classification?

3. 11. 2022 Source: Multiple Sclerosis

What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in the current classification? And what will future therapy look like?

Protective Effect of SGLT2 Inhibitors on Heart Muscle Function -⁠ Findings from a Recent Meta-analysis

Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage,…

3. 11. 2022 Source: Heart Failure

Efficacy of Conventional and Intensified Lifestyle Interventions in Individuals with Prediabetes According to Risk Level

Lifestyle changes can prevent the development of type 2 diabetes in individuals with prediabetes, but according to current findings, these measures fail for a significant portion of study…

2. 11. 2022 Source: Modern Treatment of Diabetes

Metformin with Extended Release in the Treatment of Prediabetes

The benefit of metformin in preventing the development of diabetes in people with prediabetes has been demonstrated in clinical studies. However, these studies evaluated immediate-release metformin,…

2. 11. 2022 Source: Modern Treatment of Diabetes

Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics

Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying metabolic profiles. A recently conducted meta-analysis by Italian authors investigated the impact of…

1. 11. 2022 Source: Modern Treatment of Schizophrenia

Prevalence of Metabolic Syndrome During 1 Year After the First Episode of Psychosis

Portuguese authors elucidated the high prevalence of metabolic syndrome and adverse metabolic parameters in individuals with the first episode of psychosis. Moreover, it significantly increased…

1. 11. 2022 Source: Modern Treatment of Schizophrenia

How Does Erdosteine Perform in Combination with Antibiotics?

Erdosteine is an oral mucoactive drug that reduces mucus viscosity by degrading disulfide bonds in the mucin polymer. It achieves this effect through a free thiol group in its main active metabolite,…

1. 11. 2022 Source: Cough Therapy

Benefit of Adding Erdosteine to Maintenance Treatment of COPD

Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In…

1. 11. 2022 Source: Cough Therapy

ERS 2022: What Insights Do Studies Focused on COPD Biomarkers Bring?

In this year's scientific program of the international congress of the European Respiratory Society (ERS 2022), there was also a lot of talk about the investigation of biomarkers of chronic…

1. 11. 2022 Source: Cough Therapy

Specific treatment of pulmonary involvement in patients with AAT deficiency −⁠ why, how, and for whom?

For patients with emphysema and decreased lung function due to alpha-1-antitrypsin deficiency (AATD), there is an approved specific treatment which involves the i.v. administration of…

1. 11. 2022 Source: Deficiency of Alpha-1-Antitrypsin

Diagnosis of AAT Deficiency According to Italian Recommendations and a Clear Algorithm for Practice

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that primarily affects the lungs and liver. It is considered a rare disease, but it is also significantly underdiagnosed. Given the…

1. 11. 2022 Source: Deficiency of Alpha-1-Antitrypsin

Does adding statins to DOACs reduce the risk of major bleeding in patients with non-valvular atrial fibrillation?

A large retrospective study, the results of which were recently published, investigated to what extent the concurrent administration of statins is associated with a lower risk of major bleeding,…

1. 11. 2022 Source: Anticoagulant Treatment

ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?

Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication…

1. 11. 2022 Source: Heart Failure

What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as…

31. 10. 2022 Source: Oncological Treatment

Alopecia Areata –⁠ Autoimmune Inflammatory Disease and a New Targeted Treatment Option

Alopecia areata (AA) is one of the non-scarring focal alopecias. It is an autoimmune disease of the hair follicle, the etiopathogenesis of which is not entirely understood. At the hair root, a…

31. 10. 2022 Source: Biological Treatment

1 … 42 43 44 45 46 … 115

Back Filter by speciality

Remove filters

Popular this week